MILAN, September 20, 2016
MILAN, September 20, 2016 /PRNewswire/ --
Zambon SpA, the pharmaceutical company of the group Zambon, has appointed Roberto Tascione as new CEO to drive the business on a global scale.
Tascione, 54 years, has a long experience in the pharmaceutical sector and started his career at Bristol Myers Squibb Italy, before leading the Primary Care and OTC divisions of Schering Plough. From 2009 to 2014 he was CEO of Gilead Italy and on May 2014 he returned to Bristol Myers Squibb as President and Chief Executive Officer Italy. Tascione also served on the General Council of Confindustria and was member of Farmindustria Board and the Committee for the Ethical Code.
"Zambonis a leading Italian excellence, with a strong tradition and a strong international outlook dating back to the'50s," said Tascione . " I amvery proudtodrivethe company inthis newstage of growth, look at new business opportunities andstrengthen our international network."
Elena Zambon, President of Zambon Spa, commented "I believe that a company with 110 years of history needs to rethink its rolein providinginnovative therapeutic solutions to patients.We aresurethat Roberto Tascionewith his long-standing experience in this sectorwill help us reach important goals.With him we share the vision ofan Open Company model that puts great attention to the development of internal talent in order for them to become agents of change."
Zambon is an Italian family business operating in the pharmaceutical and fine chemicals for 110 years with more than 2,800 employees in 19 countries in 3 continents, Europe, America and Asia. In 2015 the Group reported revenues for 670 million Euro, with 566.9 million Euro resulting from the pharmaceutical business. Founded in 1906 in Vicenza, Zambon has earned over the years a strong international reputation thanks to its high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care in addition to orphan drugs such as cystic fibrosis and treatments for Parkinson's Disease in the Central Nervous System. Zambon manufacturing is done in Italy, Switzerland, France, Brazil and China and its products are commercialized in 84 countries. For more information: http://www.zambongroup.com.
Luca Primavera - CCO
Milva Naguib- Media Relations
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.